Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 12/20 | 0.46 |
| ▸ | CTSK | P43235 | 9/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28969876 | 0.85 | CTSS (0.49) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL16185927 | 0.83 | CA1 (0.54) | CAPN1CTSSCTSKMEN1GAA | |
| SCHEMBL23626340 | 0.82 | CTSK (0.55) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL28257698 | 0.80 | CTSK (0.46) | CTSSCTSKCTSLCTSBCA2 | |
| SCHEMBL13955236 | 0.80 | CTSK (0.46) | CTSSCTSKCTSLCTSBCA2 | |
| SCHEMBL23822625 | 0.80 | CTSK (0.46) | CTSSCTSKCTSLCTSBCA2 | |
| SCHEMBL1023991 | 0.80 | CTSK (0.55) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL14030540 | 0.79 | CA1 (0.53) | CAPN1CTSSCTSKMEN1GAA | |
| SCHEMBL31276790 | 0.79 | CTSS (0.52) | CAPN1CTSSCTSKCTSLCTSB | |
| SCHEMBL31277057 | 0.79 | CTSS (0.49) | CAPN1CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398822-B1 | MODIFICATION OF FACTOR VIII | NOVO NORDISK AS (DK) | 2013-01-02 | — | — | EP | disclosed |
| EP-2398822-B1 | MODIFICATION OF FACTOR VIII | NOVO NORDISK AS (DK) | 2013-01-02 | — | — | EP | disclosed |
| US-20110306551-A1 | Modification of Factor VIII | NOVO NORDISK A/S (DK) | 2011-12-15 | — | — | US | disclosed |
| US-20110306551-A1 | Modification of Factor VIII | NOVO NORDISK A/S (DK) | 2011-12-15 | — | — | US | disclosed |
| WO-2010102886-A1 | MODIFICATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306551-A1 | Modification of Factor VIII | F8, F9, F13B | CAPN1 3038/4885CTSS 1388/4885CTSK 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.